Steven Smith,
Professor,
City of Hope Beckman Research Institute
Prof. Smith holds a B.S. in Zoology from the University of Idaho, and Ph.D. in Molecular Biology from the Molecular Biology Institute at UCLA. The Federation of American Societies Experimental Biology (FASEB) has recognized his work as a Wellcome Visiting Professor in Basic Medical Sciences and he is a Computerworld/Honors Laureate for Visionary Use of Information Technology in Medicine. He holds seven patents, and has published over 80 peer-reviewed articles. His work has been featured on the cover of Cope Magazine and Molecular Carcinogenesis. He is an Executive Editor of Analytical Biochemistry, and a member of several editorial boards.
Functional Replacement of 5-azaC-dR by 2´-deoxyriboguanylurea in the Inhibition of Human Dnmt1, Epimutagenesis, Mutagenesis, and Fragile Site Induction
Thursday, 19 April 2012 at 11:45
Add to Calendar ▼2012-04-19 11:45:002012-04-19 12:45:00Europe/LondonFunctional Replacement of 5-azaC-dR by 2´-deoxyriboguanylurea in the Inhibition of Human Dnmt1, Epimutagenesis, Mutagenesis, and Fragile Site InductionSELECTBIOenquiries@selectbiosciences.com
5-aza-2´-deoxycytidine is an inhibitor of DNA methylation, a mutagen, an epimutagen, a carcinogen, an inducer of fragile sites and a chemotherapeutic agent. Each of these functions can be replaced in human cells by 2´-deoxyriboguanylurea: its the primary breakdown product.
Add to Calendar ▼2012-04-19 00:00:002012-04-20 00:00:00Europe/LondonEpigeneticsSELECTBIOenquiries@selectbiosciences.com
Add to Calendar ▼2012-04-19 11:45:002012-04-19 12:45:00Europe/LondonFunctional Replacement of 5-azaC-dR by 2´-deoxyriboguanylurea in the Inhibition of Human Dnmt1, Epimutagenesis, Mutagenesis, and Fragile Site InductionSELECTBIOenquiries@selectbiosciences.com
